Adipopharma
adipopharma.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Latest round
Series A
Jan 2023 · 3 yr ago
Team
51-200
employees, estimated range
Backers
2
Good Growth Capital, Newton Biocapital
The money's age
Long since its last round
44 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jan 2023 | — | — | globenewswire |
Registers and programsofficial lists and records that name the company
| Legal entity | ADIPOPHARMA SAS | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Good Growth Capital 
Newton Biocapital Investors in similar startupsfunds that back the companies most like this one
backs Sweetch.com
Similar startupsby what they do, their industry and backers
Automated insulin delivery for insulin pen users. Better nights for better days.
Company Overview Rooted in two decades of discovery Santero Therapeutics is a Belgian biotechnology company developing first-in-class…
About Us NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes…
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
Now Enrolling: Clinical Trial for Type 1 Diabetes. See If You Qualify.
Damona Pharmaceuticals is developing precision neuromedicines to reverse cognitive deficits associated with brain disorders.associated with…
News
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
This novel whole-body insulin-sensitizing approach is designed to address insulin resistance independent of weight loss
Read more
Report
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
This novel whole-body insulin-sensitizing approach is designed to address insulin resistance independent of weight lossPITTSBURGH, March 23, 2026 (GLOBE NEWSWIRE) -- As GLP-1 therapies reshape obesity care, one biotech company is betting that the root cau
Read more
Report
AdipoPharma Recognized at American Diabetes Association 85th Annual Meeting for PATAS, Its First-in-Class Whole-Body Insulin-Sensitizing Compound
CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the U.S. and Belgium, was recognized at the American Diabetes Association's 85th Annual Meeting this week in Chicago for its novel and promis
Read more
Report
AdipoPharma Recognized at American Diabetes Association 85th Annual Meeting for PATAS, Its First-in-Class Whole-Body Insulin-Sensitizing Compound
CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the U.S. and Belgium, was recognized at...
Read more
Report
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
Global Investments Pave Way for Breakthrough Treatment for Type 2 DiabetesSTRASBOURG, France, Nov. 11, 2024, a biotech company headquartered in France with offices in the US and Belgium developing a novel
Read more
Report
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
Read more
Report
Report
La société biotechnologique française AdipoPharma obtient un financement de série A pour un médicament révolutionnaire contre le diabète
Newton Biocapital II mène une ronde de financement pour le premier médicament de sa catégorie traitant la résistance à l
Read more
Report
French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug
Newton Biocapital II Leads Funding Round For First-of-Its-Kind Drug to Treat Insulin ResistanceFirst Breakthrough Addressing Insulin Resistance in...
Read more
Report
Show more news
Financials
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2023 | — | Details |